New Delhi, Nov. 21 -- India's pharmaceutical exports are nearing the USD 30-billion mark, setting the stage for the next phase of industry innovation powered by Contract Research and Development Organisations (CRDMOs) and Global Capability Centers (GCCs), according to a new EY-Parthenon-OPPI report.

The study says the sector, anchored by India's dominance in generics and vaccines, a rapidly advancing CRDMO/CDMO ecosystem, and expanding GCCs, will be central to India's ambition of becoming a USD 30-35 trillion economy by 2047.

Titled "Fueling innovation, advancing equity: The power of partnerships and digital-first strategies driving Indian pharma's global dominance", the report highlights the transformative journey of India's pharmaceut...